iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021
November 08, 2021 16:30 ET
|
iBio, Inc.
BRYAN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Acquires FastPharming Manufacturing Facility®
November 03, 2021 16:47 ET
|
iBio, Inc.
- Takes Sole Ownership of CDMO Subsidiary & U.S. Manufacturing Rights - - Reduces Carrying Costs by Approximately 67% - BRYAN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)...
iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9
October 26, 2021 08:35 ET
|
iBio, Inc.
BRYAN, Texas, Oct. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
September 27, 2021 07:30 ET
|
iBio, Inc.
Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors Paired Access to RubrYc’s Antibody Discovery Platform with FastPharming® and GlycaneeringTM...
iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference
September 20, 2021 16:30 ET
|
iBio, Inc.
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021
September 20, 2021 07:30 ET
|
iBio, Inc.
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:30 ET
|
iBio, Inc.
BRYAN, Texas, Sept. 07, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Appoints William D. Clark to its Board of Directors
August 26, 2021 07:00 ET
|
iBio, Inc.
BRYAN, Texas, Aug. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming...
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics
August 25, 2021 07:30 ET
|
iBio, Inc.
– iBio licenses a novel antibody targeting regulatory T cells – – Company secures option to license additional antibodies developed with RubrYc’s predictive algorithms – – iBio acquires an equity...
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate
July 15, 2021 17:10 ET
|
iBio, Inc.
BRYAN, Texas, July 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that...